{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-017259","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.674078+00:00","generated_at":"2026-05-15T14:29:21.477616+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Champions Oncology Q3: study service rev record $16.6M (+32%); net loss $279k vs prior yr profit $4.5M","bullets":["Record study service revenue $16.6M, up 32% YoY; total revenue $16.6M vs $17.0M prior year.","GAAP net loss of $279k (incl $423k stock comp, $341k D&A) vs net income $4.5M prior year.","Adjusted EBITDA $574k, down from $5.1M prior year; cost margins compressed by outsourced radiolabeling.","Ended quarter with $7.1M cash, no debt; management reaffirms full-year positive adj. EBITDA and revenue growth.","R&D expense $2.3M, up 32% for data platform and Corellia investments."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-017259","json":"https://secwatch.observer/filing/0001628280-26-017259.json","markdown":"https://secwatch.observer/filing/0001628280-26-017259.md","text":"https://secwatch.observer/filing/0001628280-26-017259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828026017259/0001628280-26-017259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828026017259/csbr-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:29:21.477616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32aefed7c2d903606515567c6aae63e627b03174","claim":"CHAMPIONS ONCOLOGY, INC. reported third quarter of fiscal 2026, ended January 31, 2026 results: revenue $16.6 million, net income $279,000. Guidance reaffirmed.","evidence_excerpt":"reference in such a filing. --- EX-99.1 (EX-99.1) --- NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Revenue of $16.6 Million Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year Hackensack, NJ – March 12 , 2026 – Champions Oncology, Inc.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828026017259/0001628280-26-017259-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of fiscal 2026, ended January 31, 2026"},{"label":"Revenue","value":"$16.6 million"},{"label":"Net income","value":"$279,000"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}